Your SlideShare is downloading. ×

ReportsnReports – Molecular Diagnostics in Cancer Testing

1,153

Published on

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular …

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy.

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,153
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
19
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Molecular Diagnostics in Cancer TestingMolecular diagnostics is a rapidly-advancing area of research and medicine, with newtechnologies and applications being continually added. The technologies that come underthe umbrella of molecular diagnostics include first-generation amplification, DNA probes,fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profilingusing microarrays. These technologies are improving the discovery of therapeutic moleculesfor cancer, the screening, diagnosis and classification of cancer patients, and theoptimization of drug therapy.Buy Now: Molecular Diagnostics in Cancer Testing MarketBrowse All: Latest Market Research ReportsThis TriMark Publications report describes the specific segment of the in vitro diagnostics(IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests forcancer. In the current medical diagnostics market, molecular diagnostics for cancer testingoffers one of the brightest areas for growth and innovation. The confluence ofbreakthroughs in genomics, proteomics, and the development of microarray devices tomeasure analytes in the blood and various body tissues, has led to this revolutionarymarket segment offering the power of advanced analytical techniques to the diagnosis andtreatment of cancer.This report analyzes the size and growth of the molecular diagnostics market in itsapplications for cancer detection and therapy, examining the factors that influence thevarious market segments and the dollar volume of sales, both in the United States andworldwide.TABLE OF CONTENTS1. Overview1.1 Statement of Report1.2 About This Report1.3 Scope of the Report1.4 Objectives1.5 Methodology1.6 Executive Summary2. Introduction to Molecular Diagnostics2.1 Opening-up of Opportunities in Molecular Diagnostics2.2 Impact of the Human Genome Project on Molecular Diagnostics2.3 Considerations for Molecular and Clinical Diagnostics2.4 Molecular Diagnostics in the Post-Genomic Era2.5 Advances in Molecular Diagnostics Technologies2.6 Oligonucleotide Array Platforms2.7 Emerging Cancer Personalized Medicine Market2.7.1 Predictive Cancer Molecular Diagnostics
  • 2. 2.8 Companion Tests for Drug Development2.9 Opportunities for IVDMIA Companies3. Cancer Diagnostics Molecular Testing Market3.1 Market Description3.1.1 Market Overview3.1.2 Tumor Markers3.1.3 Molecular Diagnostic Markers3.1.4 Competitive Landscape3.1.5 Sales and Marketing Strategies for Cancer Tests3.1.5.1 North American Market3.1.5.2 International Markets3.1.5.3 Europe3.1.5.4 Asia-Pacific4. Molecular Diagnostic Tests for Cancer4.1 Cancer Diagnostic Tests4.1.1 Use of Genomics to Understand Cancer4.1.2 Molecular Diagnostic Tools Solutions4.1.3 Technology of Gene Expression Analysis4.1.3.1 Amplify and Detect Diminished Amounts of RNA Consistently4.1.3.2 Analyze Hundreds of Genes4.1.3.3 Employ Advanced Information Technology4.2 Breast Cancer4.2.1 Cancer Prognostic Assays4.2.1.1 Myriad Genetics (BRACA1 and BRACA2)4.2.1.2 Genomic Health (Oncotype DX)4.2.1.2.1 Single Gene Reporting (ER, PR, HER2)4.2.1.2.2 Node Positive (N+)4.2.1.2.3 Aromatase Inhibitors4.2.1.2.4 Product Development4.2.1.2.5 Product Development Opportunities in Breast Cancer4.2.1.3 InterGenetics, Inc.4.2.1.4 LabCorp (HER-2)4.2.1.5 Clarient, Inc.4.2.1.6 BioTheronostics (AviaraDx)4.2.1.7 Agendia B.V. (MammaPrint)4.2.1.8 Oncogene Science (Wilex)4.2.2 Competition and Comparison of Methods4.2.3 Competitive Structure and Market Share Analysis4.2.3.1 Breast Cancer Molecular Diagnostic Testing Market Size4.2.3.1.1 Global Market4.2.3.1.2 U.S. Market4.2.3.1.3 European Market4.2.3.2 Market Forecasts4.2.3.2.1 Revenue Forecasts4.2.3.3 Market Drivers and Restraints4.2.3.3.1 Market Drivers4.2.3.3.2 Market Restraints
  • 3. 4.2.3.4 Breast Cancer Molecular Diagnostic Testing Assay Market and Technology Trends4.2.3.4.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends4.2.3.4.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends4.2.3.4.3 Breast Cancer Testing Assay Strategic Recommendations4.3 Colorectal Cancer Molecular Diagnostics Market4.3.1 Colon Cancer Testing Platforms4.3.1.1 Genomic Testing4.3.1.1.1 IVD Multiplex Index Analysis (MIA)4.3.1.1.2 The BRAF Test4.3.1.1.3 KRAS4.3.1.1.3.1 Background on KRAS Mutation4.3.1.1.4 mSEPT94.3.1.2 Screening Test4.3.2 Players in the Colorectal Cancer Space4.3.3 Competitive Structure and Market Share Analysis4.3.3.1 Colon Cancer Molecular Diagnostic Testing Market Size4.3.3.1.1 Global Colon Cancer testing Market4.3.3.1.2 U.S. Colon Cancer testing Market4.3.3.1.3 European Colon Cancer testing Market4.3.3.2 Market Forecasts4.3.3.2.1 Revenue Forecasts4.3.3.3 Market Drivers and Restraints4.3.3.3.1 Market Drivers4.3.3.3.2 Market Restraints4.3.3.4 Colon Cancer Molecular Diagnostic Testing Assay Market and Technology Trends4.3.3.4.1 Colon Cancer Molecular Diagnostic Testing Assay Market Trends4.3.3.4.2 Colon Cancer Molecular Diagnostic Testing Assay Technology Trends4.3.3.4.3 Colon Cancer Molecular Diagnostic Testing Assay Strategic Recommendations4.4 Prostate Cancer Molecular Diagnostics Market4.5 Other Cancer Molecular Diagnostic Markets4.5.1 Bladder Cancer4.5.2 Ovarian Cancer4.5.2.1 Incidence of Ovarian Cancer4.5.2.2 Key Players in Ovarian Testing market4.5.2.3 Ovarian Cancer Market Size4.5.2.4 Ovarian Cancer Molecular Diagnostic Testing Market Size4.5.2.4.1 Global Ovarian Cancer testing Market4.5.2.4.2 U.S. Ovarian Cancer testing Market4.5.2.4.3 European Ovarian Cancer testing Market4.5.2.5 Market Forecasts4.5.2.5.1 Revenue Forecasts4.5.2.6 Market Drivers and Restraints4.5.2.6.1 Market Drivers4.5.2.6.2 Market Restraints4.5.2.7 Ovarian Cancer Molecular Diagnostic Testing Assay Market and Technology Trends4.5.2.7.1 Ovarian Cancer Molecular Diagnostic Testing Assay Market Trends4.5.2.7.2 Ovarian Cancer Molecular Diagnostic Testing Assay Technology Trends4.5.2.7.3 Ovarian Cancer Molecular Diagnostic Testing Assay Strategic Recommendations4.5.3 Lung Cancer
  • 4. 4.5.4 Melanoma4.6 Molecular Diagnostic Screening Test for Cancer4.6.1 Extreme Drug Resistance assay (Oncotech EDR Assay)4.6.2 Multidrug Resistance Protein (MRP)4.7 Companion Diagnostic Tests for Cancer Therapeutics5. Business5.1 Technology and Market Trends5.1.1 Technology Trends5.1.2 Market Trends5.2 M&A Activity5.3 Partnerships5.4 Competitive Analysis5.4.1 Primary Competitors5.4.1.1 Summary of Market Strengths, Weaknesses, Opportunities and Threats5.4.2 Industry Challenges and Strategic Recommendations5.4.3 Commercialization of Molecular Diagnostic Products5.5 SWOT Comparison of Business Models for Cancer Diagnostic Testing5.6 Intellectual Property Rights5.6.1 BRCA1 and BRCA2 Gene Patents5.6.2 Current Patent Disputes6. Reimbursement and Billing6.1 Overview6.2 Trends in Reimbursement Practice6.2.1 Medicare Reimbursement6.2.2 Analysis of ROI for MD Tests for Cancer Using Medicare Reimbursement Rules6.2.3 Reimbursement for Insight Dx, MammaPrint and Oncotype Dx6.2.4 Reimbursement for JAK2 Mutation Testing for Myeloproliferative Neoplasms6.3 Breast Cancer Tests6.4 Colon Cancer Tests6.5 Trends in Patient Care and Reimbursement6.6 Revenue Threats6.6.1 Medicare Exceptions6.6.2 Three Areas for Denial of Claims by Biomarkers6.7 Billing6.7.1 Medicare Billing Procedures6.7.2 Medicare CPT Coding Rules for Cancer Biomarkers7. Government Regulation7.1 U.S. Food and Drug Administration7.2 CLIA Regulations7.3 Clinical Laboratory Improvement Act (CLIA)7.4 State Licensing for Service Laboratories7.5 FDA Treatment of Multivariate Index Assays (IVDMIAs)7.6 510(k) Clearance7.7 Pre-Market Approval (PMA)7.8 ASRs7.9 What Regulatory Guidance is Needed for Companion Biomarkers?
  • 5. 7.10 U.S. Patent and Trademark Office (USPTO)7.11 IRB Approval in Clinical Trials7.12 Oncology Biomarkers Qualification Initiative Project7.13 FDA Clearance Picture for Insight Dx, MammaPrint, and Oncotype DX7.14 FDA Packaging Requirements for Erbitux7.15 Micoarray Quality Control (MAQC)7.16 CAP Evidence-based Recommendations to Improve the Accuracy of ER and PR Testing7.17 ER and PR Proficiency Testing8. Business Decisions Using Molecular Diagnostic Tests in Drug Development8.1 Advantages of a Pharmacogenomic Assessment of Genetic Biomarkers to DetermineClinical Dose8.2 What are Key Opportunities in Biomarker Discovery, Development andCommercialization?8.3 What are the Current Obstacles in Biomarker Implementation?8.4 How do Business Strategies, such as those Relating to Acquisition, Drive BiomarkerStrategies?8.5 What is the Right Balance between External Partnerships and Internal Infrastructure?8.6 How might Novel Biomarker Development Lead to Acquisition Strategies?8.7 Which Types of Genetic Biomarkers should be Developed by Diagnostic Companies?8.8 What Strategies Help Translate Genetic biomarkers from Preclinical to ClinicalDevelopment?8.9 In what Class of Drugs is the Value of Using Genetic biomarkers in Decision making theHighest?8.10 How can Regulatory Oversight Drive Approval and Adoption of New Technologies?8.11 How can Big Pharma Co-develop Genetic Biomarkers for Regulatory Acceptance?8.12 How are Genetic Biomarkers being Used to reduce the Attrition Rate in DrugDevelopment?8.13 How is ROI Measured Using Genetic Biomarkers in Drug Development?8.14 How might Organizational Structures Limit the Use of Genetic Biomarkers in DrugDevelopment and how should R&D Organizations Address this Problem?8.15 How to Maximize Business Development through Biomarker Strategies?8.16 What is the Best Type of Business Model for Developing Genetic Biomarkers?8.17 What are Organizational Impediments in Genetic Biomarkers in Drug Development?8.18 What are Internal Capabilities for Novel Biomarker Development and Application?8.19 How can Key Biomarker Technical Expertise be Applied across a Complex and Highly-Stratified R&D Value Chain?8.20 At what Stage of Drug Development has Genetic Biomarkers Provided the MostBenefit?8.21 What Companies are the most Innovative in Development of Genetic Biomarkers?8.22 Best Values for Genetic Biomarkers in Drug Development and in Diagnostics8.23 Molecular Diagnostic Tests can Increase Value in an Associated Drug9. Company Profiles9.1 Agendia9.2 ArcticDx, Inc.9.3 Arcxis Biotechnologies9.4 Aureon Laboratories9.5 Biodesix
  • 6. 9.6 bioTheranostics (AviaraDx)9.7 Clarient, Inc.9.8 CombiMatrix Corporation9.9 Epigenomics9.10 Exact Sciences Corporation9.11 Exagen Diagnostics, Inc.9.12 Exiqon9.13 Ferrer inCode9.14 Genomic Health, Inc.9.15 Genoptix, Inc.9.16 Gen-Probe9.17 InterGenetics, Inc.9.18 LabCorp9.19 Myriad Genetics, Inc.9.20 Nuvera Biosciences9.21 Orion Genomics9.22 QIAGEN NV9.23 Rosetta Genomics Ltd.9.24 Seegene9.25 Sequenom, Inc.9.26 SABiosciences Corporation9.27 Source MDx9.28 Targeted Molecular Diagnostics9.29 Xenomics, Inc.Appendix 1: Definition of Terms for Molecular DiagnosticsAppendix 2: Standard Cancer Therapeutic PanelsAppendix 3: Menu of Specialized Technologies Used to Assess and Characterize CancerAppendix 4: Technical Assessment of the KRAS Mutation Test by Several Methodologies andSpecialty Oncology LaboratoriesAppendix 5: Overview of MicroarraysLIST OF FIGURESFigure 2.1: Finding Genes with MicroassaysFigure 2.2: Use of Microassays for Studying Gene ExpressionFigure 2.3: Using DNA Microarrays to Compare Cancer and Normal CellsFigure 2.4: Microarrays for Prediction of Survival in CancerFigure 2.5: Finding New Drugs with MicroarraysFigure 2.6: Using Gene Expression Patterns to Chose TreatmentFigure 2.7: Segmentation of the Biomarker Development MarketFigure 3.1: Molecular Diagnostic Markets for Cancer Testing Globally, 2010Figure 3.2: Molecular Diagnostic Markets for Cancer Testing U.S., 2010Figure 3.3: Key Players Market Share in Global Molecular Diagnostics Cancer TestingMarketsFigure 3.4: Market Growth and Evolution of MD Cancer BiomarkersFigure 4.1: Using DNA Microassays to Measure Gene ExpressionFigure 4.2: Schematic of Molecular Diagnostics for Studying Gene Expression in PatientsFigure 4.3: HER-2/NEU Protein as a Target in Cancer TherapyFigure 4.4: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal Results with
  • 7. IHCFigure 4.5: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by FISHFigure 4.6: Action of Herceptin in Breast Cancer PatientsFigure 4.7: Analysis of Cancer Tissue by MicroarrayFigure 4.8: Global Market Size and Share of Breast Cancer Molecular Diagnostic Market,2010Figure 4.9: Incidence of CRC by Age GroupFigure 4.10: HNPCC Mutation Increases Risk of CancerFigure 4.11: APC Mutation Increases the Risk of CancerFigure 4.12: U.S. Market Share of Colon Cancer Molecular Diagnostic Market, 2010Figure 4.13: Prostate-Specific Membrane AntigenFigure 4.14: PCA3 Score NomogramFigure 4.15: Estimates for PCA3 Test Volume in U.S., 2005-2008Figure 4.16: U.S. Market Share of Ovarian Cancer Molecular Diagnostic Market, 2010Figure 5.1: FDA Co-developed Products as a Model for CollaborationFigure 5.2: Segmentation of the Biomarker Development MarketFigure 6.1: Number of Oncotype DX Tests Performed, 1991-2011Figure 7.1: OBQI and the Relationship of Governmental Regulatory AgenciesFigure 8.1: Discovery, Validation and Use of Genetic BiomarkersLIST OF TABLESTable 2.1: Genes and Cancer RiskTable 2.2: Use of Cancer Biomarkers to Enhance Patient CareTable 2.3: Targeted Drug Therapies for CancersTable 2.4: Use of Cancer Biomarkers in Drug DevelopmentTable 2.5: Utility of Biomarkers as Companion Diagnostics to Drug DevelopmentTable 2.6: Time Line for Development of Companion DiagnosticsTable 3.1: Global Market for Molecular Diagnostics Cancer Testing, 2008-2016Table 3.2: U.S. Market for Molecular Diagnostics Cancer Testing, 2008-2016Table 3.3: Molecular Diagnostic Markets for Cancer Testing, 2010Table 3.4: Key Players and Market Share in Global Molecular Diagnostics Cancer TestingMarketTable 3.5: Business Factors Influencing Advanced Oncology Testing ServicesTable 3.6: Specific Diagnostic Products Categories Comprising the Cancer Diagnostic MarketTable 3.7: In Vitro Cancer BioMarker Market Segments Worldwide, 2007 and 2010Table 3.8: Tumor Markers Currently in Common UseTable 3.9: Global IVD Cancer Tumor Marker Testing Market Segments Growth RatesTable 3.10: Worldwide Market Size in Dollar Volume for Tumor Marker Assays ProductMarket, 2001-2010Table 3.11: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market,2001-2010Table 3.12: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010Table 3.13: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010Table 3.14: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010Table 3.15: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010Table 3.16: Global Distribution of IVD Cancer Tumor Marker Diagnostic TestingTable 3.17: Market Share of Major Competitors in U.S. Cancer Tumor Marker DiagnosticsMarketTable 3.18: Major Presence in Cancer Tumor Marker Diagnostics Markets
  • 8. Table 3.19: Highlights of the Cancer Diagnostic Testing SegmentTable 3.20: Highlights of Certified Clinical Labs Specializing in CancerGenetics and Molecular Diagnostic ServicesTable 3.21: Strategies for Marketing Cancer Diagnostic ProductsTable 3.22: Key Elements of MD Diagnostic Companies Marketing PlanTable 4.1: Estimates for the Leading Sites of New Cancer Cases and Deaths in the U.S. byGenderTable 4.2: Emerging Molecular Diagnostic TechnologiesTable 4.3: Key Elements for Business Competition in Gene Expression Profiling for CancerTable 4.4: Key Elements for Future Success in the Gene Profiling for CancerSegmentTable 4.5: Companies Marketing Products in the Cancer Molecular Diagnostics SectorTable 4.6: Breast Cancer OverviewTable 4.7: Overview of ER/PR Testing and Response to TherapyTable 4.8: Key Players in the Breast Cancer Molecular Diagnostic SpaceTable 4.9: Commercially Available Molecular Diagnostic Products for Breast Cancer AssayTable 4.10: Clinical Utility and Health Economic Benefits of Oncotype DXTable 4.11: Overview of HER2/neu and HerceptinTable 4.12: MammaPrint: Key FeaturesTable 4.13: Oncogene Science Biomarker Group ReagentsTable 4.14: Major Companies Marketing Breast Cancer Molecular Diagnostic Tests, 2010Table 4.15: Global Market for Breast Cancer Molecular Diagnostic Testing, 2005-2010Table 4.16: U.S. Market for Breast Cancer Molecular Diagnostic Testing, 2005-2010Table 4.17: Global Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2011-2016Table 4.18: U.S. Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2011-2016Table 4.19: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked inOrder of ImpactTable 4.20: Breast Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked inOrder of ImpactTable 4.21: Summary of Strengths, Weaknesses, Opportunities and Threats of the BreastCancer Molecular Diagnostic MarketTable 4.22: Colorectal Cancer OverviewTable 4.23: KRAS Mutation AssayTable 4.24: KRAS Assays by Analytical TypeTable 4.25: KRAS Mutation Analysis SummaryTable 4.26: DxS KRAS Mutation Test SummaryTable 4.27: KRAS and BRAF in Clinical UseTable 4.28: Product Development Opportunities in Cancer Tumor Types, 2008Table 4.29: Key Players in the Colorectal Cancer Molecular Diagnostic SpaceTable 4.30: ArcticDx Genetic Test, Colo RiskTable 4.31: NexCourse CRC Test Offering and Treatment DirectionTable 4.32: Global Market for Molecular Diagnostic Colon Cancer Testing, 2005-2010Table 4.33: U.S. Market for Molecular Diagnostic Colon Cancer Testing, 2005-2010Table 4.34: Global Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2011-2016Table 4.35: U.S. Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2010-2016Table 4.36: Colon Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked inOrder of Impact
  • 9. Table 4.37: Colon Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked inOrder of ImpactTable 4.38: Summary of Strengths, Weaknesses, Opportunities and Threats of the ColonCancer MarketTable 4.39: Players in the Prostate Cancer Molecular Diagnostic SpaceTable 4.40: Gen-Probe Genetic Testing Product LineTable 4.41: Players in the Bladder Cancer Molecular Diagnostic SpaceTable 4.42: Commercially Available Molecular Diagnostic Products for Ovarian Caner AssayTable 4.43: Global Market for Molecular Diagnostic Ovarian Cancer Testing, 2005-2010Table 4.44: U.S. Market for Molecular Diagnostic Ovarian Cancer Testing, 2005-2010Table 4.45: Global Market Forecast for Ovarian Cancer Molecular Diagnostic Testing, 2011-2016Table 4.46: U.S. Market Forecast for Ovarian Cancer Molecular Diagnostic Testing, 2010-2016Table 4.47: Ovarian Cancer Molecular Diagnostic Testing Market: Market Drivers in Order ofImpactTable 4.48: Ovarian Cancer Molecular Diagnostic Testing Market: Market Restraints in Orderof ImpactTable 4.49: Summary of Strengths, Weaknesses, Opportunities and Threats of the OvarianCancer MarketTable 4.50: Lung Cancer Survival RatesTable 4.51: Lung Cancer FactsTable 4.52: Potential of Cancer Biomarkers in Drug Delivery and DevelopmentTable 4.53: Barriers to Adoption of Biomarkers in Clinical UseTable 5.1: Technology Trends in Cancer TestingTable 5.2: Trends in TheranosticsTable 5.3: Market Trends in Cancer TestingTable 5.4: Molecular Diagnostics Cancer Market: Market Drivers Ranked in Order of ImpactTable 5.5: Molecular Diagnostics Cancer Market: Market Restraints Ranked in Order ofImpactTable 5.6: Companies That Offer Products to Profile Gene Expression in Breast CancerTable 5.7: Principal Competitive Factors in the Cancer Screening MarketTable 5.8: Summary of Strengths, Weaknesses, Opportunities and Threats of the GlucosePoint of Care MarketTable 5.9: Molecular Diagnostics Cancer Market: Strategic Recommendations on MolecularDiagnostic Sector Business FunctionsTable 5.10: Total Molecular Diagnostics Cancer Market: Impact of Top Industry Challenges(U.S.)Table 5.11: Utility of Biomarkers as Companion Diagnostics to Drug DevelopmentTable 6.1: CPT Codes for Tumor MarkersTable 6.2: Genomic Health Oncotype DX Sales, 2006-2010Table 6.3: Drivers in KRAS TestingTable 6.4: Factors Determining Third-Party Payment for Advanced Cancer TestsTable 7.1: Rules that Affect the Ability of a Cancer Diagnostic Service Lab to ConductBusinessTable 7.2: Focus Areas for the FDA Critical Path InitiativeTable A1: Tumor Markers Currently in Common Use
  • 10. Latest Market Research Reports:Global and China Laser Equipment and Processing Industry Report, 2010-2013China Port Industry Report, 2011Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016)China Third-party Payment Industry Report, 2010-2013Global and China Wafer Foundry Industry Report, 2010-2011China Steel Structure Industry Report, 2010-2015China – Telecoms, Mobile, Broadband and ForecastsAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: +1-888-989-8004 EXT 106E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comBlog: http://www.reportsnreportsblog.com

×